Take a trial of UK to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 6th Aug, paid: 25th Sep more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +13.6%

FINANCIAL BRIEF: For the six months ended 30 June 2014, Reckitt Benckiser Group Plc revenues decreased 7% to L4.67B. Net income increased 23% to L812M. Revenues reflect Hygiene segment decrease of 8% to L1.83B, Home Care segment decrease of 11% to L871M, Pharmaceuticals/RBP segment decrease of 14% to L344M, Latin America, North & South Asia, Newzealand (LAPAC) segment decrease of 8% to L1.18B, Russia, Middle East. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
A-
A-

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: 5,229 (-2.41% below Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +3.6% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
24 brokers Broker Consensus Trend
Broker Recommendations for Reckitt Benckiser
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 3 2 12 4 5

Named Brokers and Analysts
Jefferies & Company, Inc. Martin Deboo , Credit Suisse Charlie Mills , Commerzbank Corporates & Markets Andreas Riemann , Sanford Bernstein Andrew Wood , Investec Bank (UK) Plc Nicola Mallard , Canaccord Genuity Eddy Hargreaves , ING FM , Nomura Securities Guillaume Delmas , Panmure Gordon , Santander GBM , Numis Securities , Collins Stewart & Co , Mirabaud Securities J. Lakin , CA Cheuvreux , Societe Generale Chas Manso , UniCredit Research , Berenberg James Targett , Charles Stanley Tom Gidley-Kitchin , MF Global (Historical) , Raymond James Euro Equities Hermine De Bentzmann , Shore Capital Stockbrokers Darren Shirley , Bryan Garnier , Espirito Santo Investment Bank Stephanie Barsdorf , Morningstar, Inc. Erin Lash , Day by Day Valérie GASTALDY , Liberum , BTIG April Scee , Alphavalue Armelle Moulin ,

Reckitt Benckiser Group Plc is manufacturer and marketer of branded products in household, health and personal care, selling a range through over 60 operating companies into nearly 200 countries. The Company analyses its revenue based on health, hygiene, home and portfolio brands together with RB Pharmaceuticals and Food. The Company’s geographical segments include: Europe and North America (ENA); Latin America, North Asia, South East Asia and Australia and New Zealand (LAPAC); and Russia and CIS, Middle East, North Africa, Turkey and Sub-Saharan Africa (RUMEA).The Company’s key brands include Durex, Gaviscon, Mucinex, Nurofen, Scholl, Strepsils, Airborne, MegaRed, Move Free, Bang, Clearasil, Dettol, Finish, Harpic, Lysol, Mortein, Veet Air Wick, Calgon, Vanish, Woolite and French’s.

Directors: Rakesh Kapoor (CEO) , Adrian Hennah (CFO) 56, Heather Allen (EVP) , Rob de Groot (EVP) , Amedeo Fasano (EVP) , Roberto Funari (EVP) , Frederic Larmuseau (EVP) , Simon Nash (SVP) , Gareth Hill (SVP) , Elizabeth Richardson (SEC) , Adrian Bellamy (NEC) 72, Peter Harf (NVC) 68, Jaspal Bindra (NID) 53, Nicandro Durante (NID) 57, Kenneth Hydon (NID) 68,

No. of Employees: 37,100 No. of Shareholders: 24,142


Last Annual December 31st, 2013
Last Interim June 30th, 2014
Shares in Issue 721,645,611
Free Float 637.6m (88.3%)
ISIN GB00B24CGK77

Address 103-105 Bath RoadSLOUGH, SLOUGH, SL1 3UH, United Kingdom
Web http://www.rb.com
Phone +44 1753 217800
Contact Richard Joyce (Director - Investor Relations)
Auditors PricewaterhouseCoopers LLP

RB. Share Price Performance RB. Quote
5345p
-15.0  -0.3%
Traded 5:08pm · Minimum 15 min delayed · NMS: 0.500k

Latest RB. News Announcements (delayed)

Upcoming RB. Events
Tuesday 21st October, 2014
Q3 2014 Reckitt Benckiser Group PLC Interim Management Statement
Monday 9th February, 2015 (estimate)
Q3 2014 Reckitt Benckiser Group PLC Earnings Release
Thursday 7th May, 2015 (estimate)
Reckitt Benckiser Group PLC Annual Shareholders Meeting

Recent ↓
Tuesday 16th September, 2014
Reckitt Benckiser Group PLC at Bank of America Merrill Lynch Global Consumer & Retail Conference
Wednesday 6th August, 2014
Dividend For RBGLY
Monday 28th July, 2014
H1 2014 Reckitt Benckiser Group PLC Earnings Call
Monday 28th July, 2014
H1 2014 Reckitt Benckiser Group PLC Earnings Release
Wednesday 14th May, 2014
Reckitt Benckiser plc at Credit Suisse Stockholm Consumer and Healthcare IR Day
Wednesday 7th May, 2014
Reckitt Benckiser plc Annual Shareholder Meeting
Wednesday 16th April, 2014
Q1 2014 Reckitt Benckiser plc Interim Management Statement Conference Call
Wednesday 16th April, 2014
Q1 2014 Reckitt Benckiser Group PLC Interim Management Statement
Wednesday 12th March, 2014
Reckitt Benckiser plc at Citi West Coast Symposium
Wednesday 19th February, 2014
Dividend For RBGLY


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy RB.

Access RB. Analytics Now!

FREE TRIAL or TAKE THE TOUR